BioCardia, Inc.
Extracted from this filing and checked against the source text.
BioCardia, Inc. shareholders approved Resolution Indicating how Frequently to Hold an Advisory Vote on Executive Compensation at the 2023-10-18 meeting.
Proposal 4 – Resolution Indicating how Frequently to Hold an Advisory Vote on Executive Compensation . A frequency of every one year for an advisory vote on executive compensation was approved. 1 YEAR 2 YEARS 3 YEARS Abstentions Broker Non-votes 6,031,521 23,503 502,667 100,632 7,127,248View on SEC.gov
BioCardia, Inc. shareholders approved Election of Class I directors at the 2023-10-18 meeting.
Proposal 1 – Election of Directors . The following nominees were elected as Class I directors to serve until the 2026 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified: Nominee Votes For Withheld Broker Non-votes Peter Altman, Ph.D. 4,390,666 2,267,657 7,127,248 Bill Facteau 4,500,019 2,158,304 7,127,248View on SEC.gov
BioCardia, Inc. shareholders approved Ratification of the Appointment of Independent Registered Public Accounting Firm at the 2023-10-18 meeting.
Proposal 2 – Ratification of the Appointment of Independent Registered Public Accounting Firm. The appointment of PKF San Diego, LLP as the Company’s independent registered public accounting firm for its fiscal year ending December 31, 2023 was ratified. Votes For Votes Against Abstentions Broker Non-votes 13,062,509 695,047 28,015View on SEC.gov
BioCardia, Inc. shareholders approved Approval, on an Advisory Basis, of the Company’s Executive Compensation at the 2023-10-18 meeting.
Proposal 3 – Approval, on an Advisory Basis, of the Company ’ s Executive Compensation . The Company’s executive compensation was approved on an advisory basis. Votes For Votes Against Abstentions Broker Non-votes 4,375,841 2,264,503 17,979 7,127,248View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.